Ningshao Xia：Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial
2023-11-30
Ningshao Xia:Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
2023-11-22
Ningshao Xia: Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
2023-09-22
Ningshao Xia: Anti–Epstein–Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer
2023-09-22
Hwan-Ching Tai：Wood cellulose microfibrils have a 24-chain core-shell nanostructure in seed plants
2023-06-23
Ningshao Xia:Structure and proposed DNA delivery mechanism of a marine roseophage
2023-06-19
Ningshao Xia:Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
2023-05-31
Ningshao Xia:Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
2023-05-30
Zijian Zhou：Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries.
2023-03-09
Ningshao Xia：A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19
